SCPS — Scopus BioPharma Inc.
$0.00
+$0.00 (+0.00%)
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses.
Market Cap
$16833.00
Forward P/E
-0.0x
52-Week Range
N/A
SCPS Price History
Revenue vs. Net Income
$0
Revenue · FY2020
Annual. Net margin is shown under each year.
Free Cash Flow
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
